Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Sell Biotheranostics Cancer Test

NEW YORK (GenomeWeb News) - Molecular diagnostic test maker BioTheranostics said today that Lab21 will market and sell one of its cancer tests in the UK, Ireland, and in Middle East countries.

The BioMerieux subsidiary said that the two-year commercialization agreement covers its Theros CancerType ID cancer classifier test. The 92-gene test identifies 39 types of tumors and 64 sub-types, and is used to help doctors guide their treatment decisions for cancer patients whose tumor sites are uncertain or unknown.

"The partnership with Lab21 represents the successful transition to our second generation molecular cancer classification technology in Europe," Biotheranostics CEO Richard Ding said in a statement. "This RT-PCR based test will replace our micro-array based assay, which was licensed to Agendia in Europe."

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.